The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 336:964-965 March 27, 1997 Number 13
NextNext

Successful Use of Hydroxyurea in ß-Thalassemia Major

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Hydroxyurea has been used in the treatment of sickle cell anemia to elevate hemoglobin levels and reduce clinical complications.1 The potential usefulness of hydroxyurea in the thalassemia syndromes is considerably less clear.1,2 In patients with {beta}-thalassemia intermedia, the hematologic response to hydroxyurea alone or in combination with recombinant human erythropoietin is controversial,3,4,5 and little is known about the effectiveness of long-term therapy. The standard therapeutic approach to {beta}-thalassemia major still relies on regular blood transfusions and the use of iron chelators. In this report, we describe the clinical and hematologic response of a 20-year-old man with transfusion-dependent {beta}0. . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.